StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital
November 7, 2018 8:56 AM
BMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $203.00 (from $206.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Jazz Pharmaceuticals (JAZZ) Reports Submission of Marketing Authorization Application to European Medicines Agency for Solriamfetol
November 9, 2018 5:53 AM
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
November 7, 2018 8:57 AM
Jazz Pharmaceuticals (JAZZ) PT Lowered to $184 at RBC Capital
November 7, 2018 7:22 AM
Jazz Pharmaceuticals (JAZZ) PT Lowered to $208 at Piper Jaffray
November 7, 2018 4:37 AM
After-Hours Movers 11/06: (ARRS) (ETSY) (TWLO) Higher; (INGN) (CTSO) (ZG) Lower (more...)
November 6, 2018 5:34 PM
Form 10-Q Jazz Pharmaceuticals For: Sep 30
November 6, 2018 5:07 PM
Form 8-K Jazz Pharmaceuticals For: Nov 06
November 6, 2018 4:12 PM
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c
November 6, 2018 4:06 PM
Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results
November 6, 2018 4:05 PM
